Navigation Links
HeartWare to Present at Eighth Annual JMP Securities Research Conference
Date:5/12/2009

FRAMINGHAM, Mass. and SYDNEY, May 12 /PRNewswire-FirstCall/ -- HeartWare International, Inc. (Nasdaq: HTWR) (ASX: HIN) today announced that it is scheduled to make an investor presentation at the Eighth Annual JMP Securities Research Conference at 12:30 p.m. PT (3:30 p.m. ET) on Tuesday, May 19, 2009. The conference is being held at the Ritz-Carlton, San Francisco May 18-20.

A live webcast of the Company's presentation at the conference will be available via a link provided at www.heartware.com. An archived replay of the presentation will be available shortly after the presentation time for a period of 90 days.

About HeartWare International, Inc.

HeartWare International, Inc. develops and manufactures miniaturized implantable heart pumps, or Left Ventricular Assist Devices (LVADs), to treat patients suffering from advanced heart failure. The HeartWare(R) Ventricular Assist System features the HVAD(TM) pump, the only full-output pump designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. HeartWare has completed an international clinical trial for the device involving five investigational centres in Europe and Australia. The device is currently the subject of a 150-patient clinical trial in the United States for a Bridge-to-Transplant indication.

    For further information:

    www.heartware.com                               US Investor Relations
    Howard Leibman                                  Matt Clawson
    Director Corporate Development                  Partner
    HeartWare International, Inc.                   Allen & Caron Inc
    Email. howard.leibman@heartware.com.au          Email. '/>"/>
SOURCE HeartWare International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. HeartWare Selects Allen & Caron for Investor Relations and Corporate Communications
2. HeartWare Announces Move to an Expanded, Upgraded Manufacturing Facility
3. HeartWare Receives Conditional Approval of IDE
4. HeartWare to Present at Seventh Annual JMP Securities Research Conference
5. Thoratec Announces Definitive Agreement to Acquire HeartWare International For US$282 Million;
6. Thoratec and HeartWare Receive Request for Additional Information From Federal Trade Commission
7. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
8. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
9. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
10. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
11. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:New National Pharmaceutical Council Report Provides Guidance on Evaluating Comparative Effectiveness Studies 2Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 2Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 3Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 4Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 5Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 6Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 7Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 8Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 9Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 10Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 11Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 12Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 13Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 14Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 15Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 16Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 17Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 18Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution 2Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution 3Atkins Introduces Six Ways to Shape Up With Tasty 26amp 3B Convenient New Products 58652 1Atkins Introduces Six Ways to Shape Up With Tasty 26amp 3B Convenient New Products 58652 2Atkins Introduces Six Ways to Shape Up With Tasty 26amp 3B Convenient New Products 58652 3Healthnostics Unveils Biomedical Content Strategy for Medbioworld com 14314 1Healthnostics Unveils Biomedical Content Strategy for Medbioworld com 14314 2Instrumentation Laboratory Installs 2000th ACL TOP 28R 29 System 5144 1Instrumentation Laboratory Installs 2000th ACL TOP 28R 29 System 5144 2Instrumentation Laboratory Installs 2000th ACL TOP 28R 29 System 5144 3